Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Eleven Bio Inc (NASDAQ: EBIO)

$1.90 USD -$0.02 (-1.04%)
Last Price $1.9
Net Change $-0.02 (-1.04%)
Bid $0
Ask Price $0
Open Price $1.92
Previous Close Price $1.92
High Price $1.92
Low Price $1.86
Number of Trades 320
Volume 254,800
Fifty Two Week High $5.97 (2016-08-16)
Fifty Two Week Low $0.72 (2016-05-03)
Average Daily Volume 512,641
Share Outstanding 24,700 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $-4725
Recent Earnings $
Annual EPS $-0.01
Last Quarter EPS $
Market Capitalization $0.05B
Insider Shareholders % 0.287%
Annual Revenue $0B
No. Shares Outstanding 24,700
Inst. Shareholder % 10.22%
Annual Net Income $0B
TTM Net Profit Margin $100.2
1-Year Return 118.39%
3-Year Return -85.92%
5-Year Return -82.49%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -4725%
Dividends per Share $
Stock Split Ratio
Beta 3.44
Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.

EBIO News & Stock Updates